- Home
- RARE vs TENB Comparison
RARE vs TENB Comparison
Compare RARE & TENB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RARE | TENB |
|---|---|---|
| Founded | 2010 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.5B |
| IPO Year | 2014 | 2018 |
Fundamental Metrics
Financial Performance| Metric | RARE | TENB |
|---|---|---|
| Price | $33.60 | $26.66 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 17 |
| Target Price | ★ $85.20 | $39.25 |
| AVG Volume (30 Days) | ★ 1.4M | 1.1M |
| Earning Date | 11-04-2025 | 10-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $630,598,000.00 | ★ $974,603,000.00 |
| Revenue This Year | $19.65 | $12.22 |
| Revenue Next Year | $23.65 | $7.62 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 20.63 | 11.05 |
| 52 Week Low | $25.81 | $25.28 |
| 52 Week High | $50.00 | $45.45 |
Technical Indicators
Market Signals| Indicator | RARE | TENB |
|---|---|---|
| Relative Strength Index (RSI) | 52.82 | 41.86 |
| Support Level | $32.06 | $26.18 |
| Resistance Level | $34.77 | $26.65 |
| Average True Range (ATR) | 1.40 | 0.68 |
| MACD | 0.08 | 0.09 |
| Stochastic Oscillator | 66.67 | 38.76 |
Price Performance
Historical ComparisonAbout RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About TENB Tenable Holdings Inc.
Founded in 2002, Tenable is a cybersecurity company that began providing vulnerability management solutions under its Nessus software. In recent years, Tenable has expanded its portfolio to provide a broader range of exposure management modules. Solutions include cloud security and compliance, active directory management, operational technology security and advanced vulnerability analytics. The Maryland-based company went public in 2018.